STOUGHTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2025 financial results before the...
1 Profitable Stock on Our Watchlist and 2 That Underwhelm
STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD product,...
3 Small-Cap Stocks We’re Skeptical Of
– Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM ® Net Revenue Expected in the Range of $190 Million to $200 Million – – Adjusted EBITDA*...
3 Russell 2000 Stocks Walking a Fine Line
STOUGHTON, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced the closing of its inaugural syndicated credit facility. The new aggregate $980 million...
2 Reasons to Avoid COLL and 1 Stock to Buy Instead
3 Cash-Producing Stocks We Think Twice About
3 Unpopular Stocks We Find Risky